Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Compass Pathways plc
Headquarters: London, United Kingdom
Website: http://compasspathways.com
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Kabir Kumar Nath, MBA
Number Of Employees: 166
Enterprise Value: $121,808,370
PE Ratio: -1.34
Exchange/Ticker 1: NASDAQ:CMPS
Exchange/Ticker 2: N/A
Latest Market Cap: $211,826,288
BioCentury | Jan 22, 2025
Management Tracks
Fabrice Chouraqui to become CEO of Pharming
Plus: Woodcock, Kim join Friends of Cancer Research’s board and updates from Recursion, Medtronic and more
BioCentury | Aug 20, 2024
Politics, Policy & Law
Drug pricing, psychedelic setback & Back to School preview — a BioCentury podcast
Medicare drug prices revealed. Avoiding Lykos’ lapses. Translating from target to product
BioCentury | Aug 17, 2024
Product Development
How the next psychedelics companies believe they can avoid Lykos’ fate
Functional unblinding, expectation bias are surmountable hurdles
BioCentury | Jun 28, 2024
Management Tracks
Forbion taps Dyne vet Brumm to guide growing U.S. presence
Plus: Edward Dulac to become CFO at Intellia, and updates from Altimmune, Bayer, Compass, Sensorion and Neurona
BioCentury | Feb 13, 2024
Product Development
ADCs, psychedelics & biotech IPOs: BioCentury’s latest podcast
Plus: Gilead’s $4.3B takeout of CymaBay
BioCentury | Feb 6, 2024
Product Development
Bringing psychedelics into the drug development fold
Second-generation psychedelics are being tested in more conventional clinical trials, and starting to yield impressive efficacy
BioCentury | Dec 9, 2023
Management Tracks
BMS dealmaker Mily to depart
Plus: CCO Olinger leaving Amylyx and updates from Coherus, Compass and NanoMosaic
BioCentury | Aug 19, 2023
Product Development
Psychedelic pipeline moves toward proof of concept
But the field’s biggest question won’t be answered for a while: whether it’s possible to take the psychedelic out of psychedelics
BioCentury | Aug 17, 2023
Finance
Aug. 16 Quick Takes: CirCode follows Pfizer deal with JJDC-led series A
Plus: At last, approval Ipsen FOP therapy Sohono and updates from Compass Pathways, Day One-Sprint, Seagen, Artiva, Precision-Imugene, Impel
BioCentury | Jun 1, 2023
Management Tracks
Cayer joins Ashvattha as CFO
Plus: Toleikis to continue as Sernova CEO and updates from Hinge and Compass
Items per page:
1 - 10 of 18